News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer
Breast Cancer/canceronco.com
Feb 7, 2025, 13:25

Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer

Giampaolo Bianchini, Head of the Translational and Immunotherapy Research Group at the San Raffaele Scientific Institute – Milan, shared on X:

“IMpassion030 just out in JAMA! A negative trial, but a crucial lesson:

In TNBC (as in many solid tumors), peri-operative chemo-immunotherapy is more effective than adjuvant chemo-immunotherapy.”

Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical Trial | Breast Cancer | JAMA | JAMA Network

Authors: Michail Ignatiadis, Andrew Bailey, Heather McArthur, Sarra El-abed, Evandro de Azambuja, Otto Metzger, Stephen Y. Chui,  Max Dieterich, Thomas Perretti,  Esther Shearer-Kang, Luciana Molinero, Günther G. Steger, Jacek Jassem, Soo Chin Lee, Michaela Higgins, Jose Zarba, Marcus Schmidt, Henry Gomez, Angel Guerrero Zotano, Luca Moscetti, Joanne Chiu, Elisabetta Munzone, Noa Efrat Ben-Baruch, Emilio Bajetta, Shinji Ohno, Seock-Ah Im, Gustavo Werutsky, Einav Nili Gal-Yam, Xavier Gonzalez Farre, Ling-Ming Tseng, William Jacot, Oleg Gluz, Zhimin Shao, Yaroslav Shparyk, Anastasia Zimina, Eric Winer, David A. Cameron, Giuseppe Viale, Shigehira Saji, Richard Gelber, Martine Piccart

Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer

Anastasia Zimina Andrew Bailey Angel Guerrero-Zotano cancer David A Cameron Einav Nili Gal-Yam Elisabetta Munzone Emilio Bajetta Eric Winer Esther Shearer-Kang Evandro de Azambuja Giampaolo Bianchini Giuseppe Viale Günther G. Steger Gustavo Werutsky Heather McArthur Henry Gomez Jacek Jassem Joanne Chiu Jose Zarba Ling-Ming Tseng Luca Moscetti Luciana Molinero Marcus Schmidt Martine Piccart Max Dieterich Michaela Higgins Michail ignatiadis Noa Efrat Ben-Baruch Oleg Gluz OncoDaily Oncology Otto Metzger Richard Gelber Sarra El-abed Seock-Ah Im Shigehira Saji Shinji Ohno Soo Chin Lee Stephen Y. Chui Thomas Perretti William Jacot Xavier Gonzalez-Farré Yaroslav Shparyk Zhimin Shao
Special Coverage
Insight
Feb 7, 2025, 13:25
Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer
Blog
Feb 7, 2025, 13:19
Yasser Mohamed Ali Ged: IO Combination Therapy for Metastatic MiT Family Translocation Renal Cell Carcinoma
Career
Feb 7, 2025, 13:18
Pfizer Announced Jeffrey Legos As Their New Chief Oncology Officer
Blog
Feb 7, 2025, 13:16
Kamila Naxerova: Quantifying cell divisions along evolutionary lineages in cancer
Blog
Feb 7, 2025, 13:15
Roni Shouval: Treatment failure patterns in early vs late introduction of CAR T-cell therapy in large B-cell lymphoma
Blog
Feb 7, 2025, 13:13
Paolo Tarantino: Grateful to receive a Research Award from METAvivor to advance MBC research
Science
Feb 7, 2025, 13:10
Advances in Hepatocellular Carcinoma: A Comprehensive Update on Epidemiology, Diagnosis, and Treatment
Blog
Feb 7, 2025, 13:09
Donna Feild: Highlighting the success stories, the breakthroughs that have improved the quality of life for patients worldwide
Science
Feb 7, 2025, 12:58
Myeloma Paper of the Day, February 7th, suggested by Robert Orlowski
Drugs
Feb 7, 2025, 12:36
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
Blog
Feb 7, 2025, 12:34
Double CHEK2 Pathogenic and Low-Risk Variants and Associated Cancer Phenotypes
Drugs
Feb 7, 2025, 12:32
Benjamin Weinberg: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer